EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205

British Journal of Cancer

Volumn 111, Issue 5, 2014, Pages 955-964

  Massoner, P ^a,b   Thomm, T ^b   Mack, B ^b   Untergasser, G ^c   Martowicz, A ^c   Bobowski, K ^b   Klocker, H ^a   Gires, O ^b   Puhr, M ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF MUNICH   (Germany)

^c TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

chemotherapy resistance; docetaxel; EMT; EpCAM; expression; prostate cancer

Indexed keywords

DOCETAXEL; EPITHELIAL CELL ADHESION MOLECULE; MESSENGER RNA; MICRORNA 200C; MICRORNA 205;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; METASTASIS; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS; RNA, MESSENGER; TAXOIDS;

EID: 84906937781     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.366     Document Type: Article

References (56)

1. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10: 6897-6904.
2. Ammons WS, Bauer RJ, Horwitz AH, Chen ZJ, Bautista E, Ruan HH, Abramova M, Scott KR, Dedrick RL (2003) In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule. Neoplasia 5: 146-154.
3. Baeuerle PA, Gires O (2007) EpCAM (CD326) finding its role in cancer. Br J Cancer 96: 417-423.
4. Balzar M, Prins FA, Bakker HA, Fleuren GJ, Warnaar SO, Litvinov SV (1999) The structural analysis of adhesions mediated by Ep-CAM. Exp Cell Res 246: 108-121.
5. Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W, Schennach H, Schafer G, Frauscher F, Boniol M, Severi G, Robertson C, Boyle P (2008) Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 101: 809-816.
6. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS (1997) Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18: 1215-1223.
7. Benko G, Spajic B, Kruslin B, Tomas D (2011) Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urol Oncol 31(4): 468-474.
8. Brock R, Hamelers IH, Jovin TM (1999) Comparison of fixation protocols for adherent cultured cells applied to a GFP fusion protein of the epidermal growth factor receptor. Cytometry 35: 353-362.
9. Chaudry MA, Sales K, Ruf P, Lindhofer H, Winslet MC (2007) EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. Br J Cancer 96: 1013-1019.
10. Chaves-Perez A, Mack B, Maetzel D, Kremling H, Eggert C, Harreus U, Gires O (2012) EpCAM regulates cell cycle progression via control of cyclin D1 expression. Oncogene 32(5): 641-650.
11. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A,Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791.
12. Denzel S, Maetzel D, Mack B, Eggert C, Barr G, Gires O (2009) Initial activation of EpCAM cleavage via cell-to-cell contact. BMC Cancer 9: 402.
13. Detre S, Jotti GS, Dowsett M (1995) A ''quickscore'' method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48: 876-878.
14. Di Paolo C,Willuda J, Kubetzko S, Lauffer I, Tschudi D,Waibel R, Pluckthun A, Stahel RA, Zangemeister-Wittke U (2003) A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific singlechain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 9: 2837-2848.
15. Driemel C, Kremling H, Schumacher S, Will D, Wolters J, Lindenlauf N, Mack B, Baldus SA, Hoya V, Pietsch JM, Panagiotidou P, Raba K, Vay C, Vallböhmer D, Harréus U, Knoefel WT, Stoecklein NH, Gires O (2013) Context-dependent adaption of EpCAM expression in early systemic esophageal cancer. Oncogene; e-pub ahead of print 21 October 2013; doi:10.1038/onc.2013. 441.
16. Fournier P, Schirrmacher V (2013) Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer preparing for the future. BioDrugs 27: 35-53.
17. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G (2000) Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 356: 1981-1982.
18. Gorges TM, Tinhofer I, DroschM, Roese L, Zollner TM, Krahn T, von Ahsen O (2012) Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 12: 178.
19. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601.
20. Hachmeister M, Bobowski KD, Hogl S, Dislich B, Fukumori A, Eggert C, Mack B, Kremling H, Sarrach S, Coscia F, Zimmermann W, Steiner H, Lichtenthaler SF, Gires O (2013) Regulated Intramembrane Proteolysis and Degradation of Murine Epithelial Cell Adhesion Molecule mEpCAM. PLoS One 8: e71836.
21. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
22. Heideman DAM, Snijders PJF, Craanen ME, Bloemena E, Meijer C, Meuwissen SGM, van Beusechem VW, Pinedo HM, Curiel DT, Haisma HJ, Gerritsen WR (2001) Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Ther 8: 342-351.
23. Jojovic M, Adam E, Zangemeister-Wittke U, Schumacher U (1998) Epithelial glycoprotein-2 expression is subject to regulatory processes in epithelial-mesenchymal transitions during metastases: an investigation of human cancers transplanted into severe combined immunodeficient mice. Histochem J 30: 723-729.
24. Kogan I, Goldfinger N, Milyavsky M, Cohen M, Shats I, Dobler G, Klocker H, Wasylyk B, Voller M, Aalders T, Schalken JA, Oren M, Rotter V (2006) hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. Cancer Res 66: 3531-3540.
25. Konigsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M, Wrba F, de Santis M, Zeillinger R, Hudec M, Dittrich C (2011) Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol 50: 700-710.
26. Kuner R, Falth M, Pressinotti NC, Brase JC, Puig SB, Metzger J, Gade S, Schafer G, Bartsch G, Steiner E, Klocker H, Sultmann H (2012) The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer. J Mol Med (Berl) 91: 237-248.
27. Maaser K, Borlak J (2008) A genome-wide expression analysis identifies a network of EpCAM-induced cell cycle regulators. Br J Cancer 99: 1635-1643.
28. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M, Gires O (2009) Nuclear signalling by tumourassociated antigen EpCAM. Nat Cell Biol 11: 162-171.
29. Martowicz A, Spizzo G, Gastl G, Untergasser G (2012) Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines. BMC Cancer 12: 501.
30. Massoner P, Kugler KG, Unterberger K, Kuner R, Mueller LA, Falth M, Schafer G, Seifarth C, Ecker S, Verdorfer I, Graber A, Sultmann H, Klocker H (2013) Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y. PLoS One 8: e55207.
31. Mellstedt H, Fagerberg J, Frodin JE, Hjelm-Skog AL, Liljefors M, Markovic K, Mosolits S, Ragnhammar P (2000) Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma. Ann N Y Acad Sci 910: 254-262.
32. Moldenhauer G, Momburg F, Moller P, Schwartz R, Hammerling GJ (1987) Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Br J Cancer 56: 714-721.
33. Munz M, Fellinger K, Hofmann T, Schmitt B, Gires O (2008) Glycosylation is crucial for stability of tumour and cancer stem cell antigen EpCAM. Front Biosci 13: 5195-5201.
34. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O (2004) The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23: 5748-5758.
35. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450: 1235-1239.
36. Ni J, Cozzi P, Hao J, Beretov J, Chang L, Duan W, Shigdar S, Delprado W, Graham P, Bucci J, Kearsley J, Li Y (2013) Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol 45: 2736-2748.
37. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, Cole DJ, Gillanders WE (2004) EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64: 5818-5824.
38. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22: 894-907.
39. Piyathilake CJ, Frost AR, Weiss H, Manne U, Heimburger DC, Grizzle WE (2000) The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung. Hum Pathol 31: 482-487.
40. Ploner C, Rainer J, Niederegger H, Eduardoff M, Villunger A, Geley S, Kofler R (2008) The BCL2 rheostat in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia. Leukemia 22: 370-377.
41. PuhrM,Hoefer J, Schafer G, ErbHH,Oh SJ, Klocker H, Heidegger I,NeuwirtH, Culig Z (2012) Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol 181: 2188-2201.
42. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6: 1-6.
43. Riesenberg R, Buchner A, Pohla H, Lindhofer H (2001) Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem 49: 911-917.
44. Riethdorf S, Wikman H, Pantel K (2008) Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 123: 1991-2006.
45. Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, Condron MM, Teplow DB, Haass C (2001) Presenilin dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep 2: 835-841.
46. Seimetz D, Lindhofer H, Bokemeyer C (2010) Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 36: 458-467.
47. Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA (2007) Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res 13: 3058-3067.
48. Strnad J, Hamilton AE, Beavers LS, Gamboa GC, Apelgren LD, Taber LD, Sportsman JR, Bumol TF, Sharp JD, Gadski RA (1989) Molecular cloning and characterization of a human adenocarcinoma/epithelial cell surface antigen complementary DNA. Cancer Res 49: 314-317.
49. Thurm H, Ebel S, Kentenich C, Hemsen A, Riethdorf S, Coith C,Wallwiener D, Braun S, Oberhoff C, Janicke F, Pantel K (2003) Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res 9: 2598-2604.
50. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
51. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC (2007) Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 171: 386-395.
52. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG (2011) EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31: 1913-1921.
53. Vannier C, Mock K, Brabletz T, Driever W (2013) Zeb1 regulates E-cadherin and Epcam (epithelial cell adhesion molecule) expression to control cell behavior in early zebrafish development. J Biol Chem 288: 18643-18659.
54. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA (2006) Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94: 128-135.
55. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S (2004) Frequent EpCam protein expression in human carcinomas. Hum Pathol 35: 122-128.
56. Wu CJ, Mannan P, Lu M, Udey MC (2013) Epithelial cell adhesion molecule (EpCAM) regulates claudin dynamics and tight junctions. J Biol Chem 288: 12253-12268.